The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
Open Access
- 30 September 2016
- journal article
- research article
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 55 (13) , 1230-1241
Abstract
This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8%) reported that >50.0% of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.Keywords
This publication has 12 references indexed in Scilit:
- Perceived Risk of Severe Respiratory Syncytial Virus Disease and Immunoprophylaxis Use Among US Pediatric SpecialistsClinical Pediatrics, 2015
- Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus InfectionPediatrics, 2014
- Practical Resources for Nurses and Other Health Care Providers Involved in the Care of Children at Risk for Respiratory Syncytial Virus InfectionNeonatal Network, 2012
- Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ PerspectiveNeonatal Network, 2012
- Respiratory Morbidity in Adulthood After Respiratory Syncytial Virus Hospitalization in InfancyThe Pediatric Infectious Disease Journal, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- A Systematic Review of Compliance with Palivizumab Administration for RSV ImmunoprophylaxisJournal of Managed Care Pharmacy, 2010
- Compliance with RSV prophylaxis: Global physicians’ perspectivesPatient Preference and Adherence, 2009
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998